Fundz

Who to call at Kashiv BioSciences, and when

Fundz watches for the moments Kashiv BioSciences starts buying, and tells you who to reach.

  • An alert the day Kashiv BioSciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kashiv BioSciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kashiv BioSciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Jul 01, 2024

Contract Type

agreement

BridgewaterManufacturingBiotechnologyHealth Care

Description

Kashiv BioSciences, LLC has announced an exclusive licensing agreement with Amneal Pharmaceuticals, Inc. for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR® for the United States. The biosimilar is currently in a Phase III clinical trial, targeting free IgE to treat chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria.

Quick answer

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) (July 1, 2024). Kashiv BioSciences is based in Bridgewater, New Jersey, United States.

What agreement did Kashiv BioSciences announce on July 1, 2024?
Kashiv BioSciences, LLC has announced an exclusive licensing agreement with Amneal Pharmaceuticals, Inc. for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR® for the United States. The biosimilar is currently in a Phase III clinical trial, targeting free IgE to treat chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic...
What does Kashiv BioSciences do?
Kashiv BioSciences, LLC is a company that focuses on developing and manufacturing high-quality, affordable biosimilars to improve patients’ lives worldwide.
Where is Kashiv BioSciences based?
Kashiv BioSciences is based in Bridgewater, New Jersey, United States.

Source: Fundz verified event record.

Company Information

Company

Kashiv BioSciences

Location

Bridgewater, New Jersey, United States

About

Kashiv BioSciences, LLC is a company that focuses on developing and manufacturing high-quality, affordable biosimilars to improve patients’ lives worldwide.

Related People

Paras
Senior decision-maker at this company
••••••••@••••••••

See Paras's verified email →

Shailesh
Senior decision-maker at this company
••••••••@••••••••

See Shailesh's verified email →

Kishore
Likely contact at this company
••••••••@••••••••

See Kishore's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Kashiv BioSciences's next move

Learn about Strategic plan

Kashiv BioSciences signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.